NeuroNews

A neurologist ordered MRI/MRA for a suspected stroke but marked it routine, not stat, and never followed up; the hospital MRI was down and the patient developed basilar thrombosis with locked-in syndrome ~24h later. Jury awarded $4.5M.

The Doctors Company's 2026 analysis of neurology malpractice claims flags diagnostic and clinical-judgment errors plus communication failures as top drivers, with a case on neuromonitoring supervision during spinal procedures.

The European Commission approved the BTK inhibitor tolebrutinib for non-relapsing secondary progressive MS — the first drug aimed at disability accumulation in this population — months after the FDA issued a complete response letter for the same indication.

FDA agreed that 3-year Phase I/II data can serve as the primary basis for accelerated approval of AMT-130 gene therapy in Huntington's disease; uniQure plans a BLA submission in Q3 2026, positioning AMT-130 as a potential first HD gene therapy.

Epicrispr reported the first clinical evidence a therapy raised muscle in FSHD: three patients gained ~370 mL of lean muscle six months after a single IV dose of DUX4-silencing EPI-321.

The AAN 2026 Clinical Trials Plenary framed neurology's shift toward interventional therapies, prevention, biomarker-informed endpoints, and adaptive designs — with NIMBLE and OCEANIC-STROKE published concurrently.

FDA approved gadoquatrane (Ambelvist), a next-generation macrocyclic gadolinium contrast agent for MRI of CNS (brain/spine) and body lesions; at 0.01 mmol/kg it is the lowest-dose gadolinium agent in the U.S., ~60% less gadolinium than standard agents.

At AHS 2026, experts spotlighted migraine targets beyond CGRP/PACAP — TRPM8, VIP, orexin, Nav1.8 — plus repurposed agents like suzetrigine and GLP-1s, and a shift toward patient-reported outcomes.

A real-world analysis at CMSC 2026 found ocrelizumab gave comparable relapse and MRI control in pediatric- and young-adult-onset MS, with greater disability improvement in the pediatric group.

Merck stopped its 349-patient phase 2 study of MK-1167, an alpha-7 nicotinic receptor modulator partnered with Neuphoria, after an interim analysis showed it failed efficacy criteria; no safety concerns cited.

FDA approved another OTC intranasal naloxone product (Rextovy, 4 mg) for emergency treatment of opioid overdose, expanding access and competition among nonprescription overdose-reversal options.

EAN 2026's closing session in Geneva recapped advances across cerebrovascular disease, MS, movement disorders, and dementia, with a theme of disease-biology insight driving personalized care.

KFF finds 99% of Medicare Advantage enrollees face prior authorization for some services — most often costly care like inpatient stays (97%) and skilled nursing (95%), but rarely preventive services (6%).

House Ways & Means advanced the bipartisan Provider Reimbursement Stability Act (44-0), raising Medicare's outdated $20M budget-neutrality threshold to $57.64M and capping annual payment swings at 2.5%.

An Interim Final Rule requires certain adult Medicaid applicants and enrollees to meet an 80-hour-per-month work requirement (via employment, education, or other qualifying activities) as a condition of eligibility.

A new CMS initiative lets eligible Medicare beneficiaries obtain certain GLP-1 medications for $50 per month, testing the impact of expanded access to these drugs.

The 2026 NRMP Match was the largest ever: 44,344 positions (up 2.6%), 53,373 registrants, 79.8% of certified applicants matched to PGY-1, and 93.3% of PGY-1 slots filled.

An essay arguing that truthfulness — including the willingness to disclose one's own errors — is the ultimate measure of a physician's character and career.

A reflective essay on the 'sacred moments' of connection with patients during vulnerability, and how contemplative practice can sustain meaning and buffer burnout.

A breakdown of the four tiers of physician disability coverage — true own-occupation, transitional, modified, and any-occupation — and how specialty and career stage should guide which policy doctors buy.

A walk through breakeven-age math for claiming Social Security at 62 versus 70 — factoring inflation, investment returns, and taxation — with a note on strategy for high-net-worth physicians.